Drug Trial Radar · NCT03427125
A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis
Last checked: Nov 19, 2026Latest source record: Jun 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,559
Actual
Start
Jan 8, 2018
Primary completion
Nov 15, 2019
Study completion Feb 27, 2020
Sponsor
- Lead sponsor
- ArdelyxIndustry
- Sponsor type
- Industry
- First posted
- Feb 9, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 3, 26-week, open label study with a 12-week, placebo-controlled, randomized withdrawal period followed by an open label long term safety extension will evaluate the safety and efficacy of tenapanor to treat hyperphosphatemia in end-stage renal disease (ESRD) on hemodialysis and peritoneal dialysis.
Conditions
- Hyperphosphatemia
Interventions
TenapanorDrug
Active Drug
PlaceboDrug
Inactive Drug
Sevelamer CarbonateDrug
Active control
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Serum Phosphorus Levels During Placebo Controlled Randomized Withdrawal Period in the Responder PopulationTime frame: 12 weeks (randomized withdrawal period)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site 529
The Bronx, New York
Wake Forest School of Medicine
Winston-Salem, North Carolina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.